Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(02)02665-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis.
J Hepatol
December 2024
Department of Medicine (DIMED), University of Padova, Italy; First Chair of Internal Medicine and Thrombotic and Haemorrhagic Disease Unit, Padova University Hospital, Padova, Italy. Electronic address:
Background & Aims: The clinical utility of thrombomodulin-modified thrombin generation (TM-TG) in cirrhosis is uncertain. We conducted a prospective study to evaluate the prognostic value of TM-TG in cirrhosis.
Methods: Patients were recruited during outpatient clinics (compensated and stable decompensated) or if admitted to our inpatient service (acutely decompensated, AD).
Hepatic immune regulation and sex disparities.
Nat Rev Gastroenterol Hepatol
December 2024
Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.
Article Synopsis
- * The liver's immune system plays a crucial role in maintaining health, and changes in immune function can lead to worsening liver conditions and fibrosis.
- * Differences in gut microbiota and their interaction with the liver's immune system may lead to variations in disease progression between sexes, highlighting the need for targeted research and potential new treatment strategies.
Risk Factors for Recurrence of Primary Sclerosing Cholangitis after Liver Transplantation: Single-Center Data.
J Pers Med
February 2024
Multivisceral Transplant Unit and Gastroenterology, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, 35128 Padova, Italy.
Background: Primary sclerosing cholangitis (PSC), comprising 5-15% of European liver transplantation (LT) cases, poses a significant challenge due to the risk of post-transplant disease recurrence (rPSC). This single-center study aimed to determine the rPSC rate and long-term post-LT outcomes in PSC patients and to identify potentially modifiable risk factors of rPSC.
Methods: All PSC patients receiving LT at Padua Hospital from 1993 to 2021 were included.
Mesenchymal Stem Cell Extracellular Vesicles as a New Treatment Paradigm in Solid Abdominal Organ Transplantation: A Case Series.
Stem Cells Dev
March 2024
Department of Abdominal Transplantation, Center for Gut Rehabilitation and Transplantation, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio, USA.
Article Synopsis
- The study investigates the use of an investigational product derived from mesenchymal stem cells to treat rejection and GVHD in solid organ transplant patients.
- Seven emergency applications were filed with the FDA to administer this product to patients experiencing graft rejection or GVHD, with treatment cycles repeated up to four times.
- Results showed no adverse events, significant clinical improvements within 24 hours, and complete resolution of graft inflammation and GVHD symptoms within a week after treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!